Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Most patients undergoing cataract surgery suffer from corneal edema after the surgery.
Brimonidine drops are a well known and safe Anti-glaucoma medication. the investigators have made several clinical observations that patients receiving Brimonidine drops had a faster resolution of their corneal edema even if they had normal intra-ocular pressure.
The investigators believe that administering topical Brimonidine to patients with significant post operative corneal edema will hasten the resolution of their corneal edema.
| Condition | Intervention | Phase |
|---|---|---|
|
Corneal Edema Visual Acuity |
Drug: Brimonidine Tartrate 0.2% Drug: Timolol maleate 0.5% |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 3 Study of Brimonidine Tartrate Drops Efficacy in Reducing Post Operative Corneal Edema After Cataract Surgery |
- central corneal thickness in micrometer [ Time Frame: day 0 (day of enrollment ), day 7, day 30 ] [ Designated as safety issue: No ]
- grading of corneal edema (1-3) [ Time Frame: day 0 (day of enrollment), day 7, day 30 ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 150 |
| Study Start Date: | January 2009 |
| Estimated Study Completion Date: | January 2010 |
| Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: brimonidine
50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops) |
Drug: Brimonidine Tartrate 0.2%
Brimonidine Tartrate 0.2% drops 1 drop twice a day for 1 month in the operated eye Other Name: ALPHAGAN P
|
|
Active Comparator: 2 tmolol
50 patients receiving timolol maleate 0.5% drops in the operated eye 1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops) |
Drug: Timolol maleate 0.5%
timolol maleate 0.5% drops 1 drop twice a day for 1 month in the operated eye Other Names:
|
|
No Intervention: 3
50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)
|
Detailed Description:
Most patients undergoing cataract surgery suffer from corneal edema after the surgery which temporarily reduces their visual acuity until corneal edema resolves over several weeks Brimonidine drops are a well known and safe Anti-glaucoma medication, used to lower intra ocular pressure.
there have been several clinical observations that patients receiving Brimonidine drops had a faster resolution of their corneal edema even in the presence of normal intra-ocular pressure.
The investigators postulated that administering topical Brimonidine to patients with significant post operative corneal edema will hasten their recovery and visual improvement.
In order to prove that Brimonidine drops contribute to faster resolution of cornel edema and visual improvement, the study will randomly compare 50 post cataract surgery patients (group A)who will be administered Brimonidine to 2 control groups (50 people in each group):
group B will be given topical timolol drops 0.5% (another well recognized anti glaucoma medication which reduces intra-ocular pressure by different mechanism than Brimonidine.
Group C will not be given any test drug. All 3 groups will receive the regular post operative medications which include corticosteroids and antibiotics.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1 day after uneventful cataract surgery
- corneal edema (grade 2 to 3)
Exclusion Criteria:
- glaucoma
- higher than normal intraocular pressure (>23 mm Hg)
- known sensitivity or contra indication to brimonidine
- known sensitivity or contra indication to timolol
- pre operative corneal or anterior segment disease
- intraoperative complications
- major ocular pathology other than corneal that reduced vision (retinal degeneration, optic neuropathy etc.)
- pregnant women
- children
Contacts and Locations| Contact: Anat Robinson, MD | 9729377176 | robina@clalit.org.il |
| Contact: Omer Y Bialer, MD | 9729377171 | omerb@clalit.org.il |
| Israel | |
| Rabin medical center ophthalmology deparment | Not yet recruiting |
| Petah-Tikva, Israel, 49100 | |
| Contact: Weinberger Dov, MD 9729376101 dwin@clalit.org.il | |
| Contact: Omer bialer, MD 9729377171 omerb@clalit.org.il | |
| Sub-Investigator: omer y bialer, MD | |
| Principal Investigator: Anat Robinson, MD | |
| Principal Investigator: | Anat Robinson, MD | Rabin medical center, Clalit health services , Israel |
More Information
No publications provided
| Responsible Party: | Dr. Robinson Anat, Rabin Medical Center |
| ClinicalTrials.gov Identifier: | NCT00800423 History of Changes |
| Other Study ID Numbers: | 5189 |
| Study First Received: | November 30, 2008 |
| Last Updated: | December 1, 2008 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Rabin Medical Center:
|
corneal edema postoperative corneal edema central corneal thickness visual acuity |
postoperative brimonidine timolol cataract surgery |
Additional relevant MeSH terms:
|
Corneal Edema Edema Cataract Corneal Diseases Eye Diseases Signs and Symptoms Lens Diseases Timolol Brimonidine Maleic acid Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Anti-Arrhythmia Agents Cardiovascular Agents Therapeutic Uses Antihypertensive Agents Enzyme Inhibitors Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists |
ClinicalTrials.gov processed this record on May 23, 2013